DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Immune cytopenias in newborns]

Author(s): Brossard Y

Affiliation(s): Centre d'hemobiologie perinatale 75570 Paris. chpparis@club-internet.fr

Publication date & source: 2001-09-15, Rev Prat., 51(14):1571-6.

Publication type: Review

Rhesus D haemolytic disease of the newborn (RH HDN) and neonatal PlA1 alloimmune thrombocytopenia (NAT) are the main immune cytopenias affecting fetal red blood cells or platelets through maternal antibodies. During RH HDN, fetal anaemia and neonatal hyperbilirubinaemia may progress, if untreated, towards fetal death and neonatal kernicterus. Likewise, during NAT, intracranial haemorrhage may occur antenally, at delivery or postnatally. Fetal and neonatal transfusion therapy, pre-term delivery, and intensive phototherapy avoid or greatly reduce the incidence of these complications. However, the best treatment of RH HDN is to prevent primary anti-D immunisation in Rh negative pregnant women through passive immunotherapy with Rh immune globulin.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017